Key result
Synthesis and screening of chromanol 293B analogues identified HMR1556 as a highly active and selective IKs-channel blocker for development as an antiarrhythmic drug.
Population
Xenopus oocytes injected with human minK (KCNE1)
Design
Preclinical
Authors
Loading...
HMR1556 merits further preclinical testing; leaves open its viability as a selective antiarrhythmic in patients.
HMR1556 was identified as a potent and selective IKs-channel blocker for potential development as an antiarrhythmic drug.
Gerlach et al. (2001) studied Arrhythmia (preclinical model). Chromanol 293B and HMR1556 was evaluated on IKs-channel blocking activity. Synthesis and screening of chromanol 293B analogues identified HMR1556 as a highly active and selective IKs-channel blocker for development as an antiarrhythmic drug.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: